Skip to content
MRD Watch

Wednesday, November 18, 2026

Subscribe
Sponsor this briefing. One site and newsletter slot, $250/week.

Cancer type

Bladder / urothelial

Bladder and urothelial cancer.

Must-know

  1. 1

    IMvigor011: ctDNA-guided adjuvant atezolizumab in muscle-invasive bladder cancer

    Powles et al. New England Journal of Medicine. 2025.

    761 patients were monitored with serial ctDNA after surgery. 250 who tested ctDNA-positive were randomized. Median disease-free survival was 9.9 months with atezolizumab and 4.8 months with placebo (hazard ratio 0.64, 95% CI 0.47–0.87). Median overall survival was 32.8 versus 21.1 months (hazard ratio 0.59, 95% CI 0.39–0.90). Among 357 patients who stayed ctDNA-negative, disease-free survival was 95% at 1 year and 88% at 2 years.

    PMID 41124204DOI

  2. 2

    IMvigor010: ctDNA after cystectomy for urothelial cancer

    Powles et al. Nature. 2021.

    The randomized trial did not meet its primary endpoint in the intention-to-treat population. ctDNA at the start of therapy was positive in 214 of 581 patients (37%). In that ctDNA-positive group, the disease-free survival hazard ratio for atezolizumab versus observation was 0.58 (95% CI 0.43–0.79). No disease-free or overall survival difference between arms was seen in the ctDNA-negative group.

    PMID 34135506DOI

  3. 3

    Serial ctDNA before and after cystectomy

    Christensen et al. Journal of Clinical Oncology. 2019.

    In 68 patients with localized advanced bladder cancer, ctDNA before chemotherapy had a hazard ratio of 29.1. After cystectomy, ctDNA identified metastatic relapse with 100% sensitivity and 98% specificity in that series, a median of 96 days before imaging.

    PMID 31059311DOI

Listed when a study is a randomized or prospective interventional ctDNA or MRD trial, is cited in NCCN or ESMO guidance, or is a prospective validation cohort in a high-impact journal. Shorter lists mean fewer studies met that rule. No test is ranked.

Publications and presentations

Presentations

  • Level 1positiveASCO Annual Meeting 2026

    Patient-reported outcomes from IMvigor011: A phase 3 study of circulating tumor (ct)DNA-guided adjuvant atezolizumab vs placebo in muscle-invasive bladder cancer (MIBC).

    Bellmunt, Joaquim · Abstract 4627 · IMvigor011 · 250 ctDNA-positive patients randomized (167 atezolizumab, 83 placebo)

    not named in the abstract

    Time to confirmed deterioration in physical functioning, role functioning, and global health status/quality of life showed no evidence of a difference between atezolizumab and placebo. More than 90% of patients in both arms reported little or no treatment side-effect burden through cycle 11. The abstract concludes ctDNA-guided adjuvant atezolizumab improved DFS and OS without negatively affecting patient-reported quality of life.

    AbstractFull paper

  • Level 1mixedASCO Genitourinary Cancers Symposium 2026

    Circulating tumor DNA (ctDNA) to guide response-adapted bladder preservation in muscle invasive bladder cancer (MIBC).

    Ghatalia, Pooja · Abstract LBA632 · LBA · RETAIN-2 (and combined RETAIN-1/2) · 71 evaluable RETAIN-2 patients; combined ctDNA analysis across RETAIN-1/2: 274 timepoints from 111 patients

    Signatera (named in the abstract)

    Estimated 2-year metastasis-free survival was 79.8% in the RETAIN-2 ITT population; the abstract states RETAIN-2 is expected to meet its primary MFS endpoint. Among 22 active-surveillance patients, 16 (73%) remained metastasis-free with an intact bladder. Post-treatment ctDNA negativity or clearance predicted lower recurrence (34.8% and 43.8%) than persistent positivity or non-clearance (85.7% and 91.7%). Among active-surveillance patients who were ctDNA-negative after treatment, 24-month MFS was 82.4% but 24-month RFS was 50.7%, driven by local recurrences: 19 of 22 who recurred on active surveillance were ctDNA-negative after treatment.

    Abstract

  • Level 3prognosticASCO Genitourinary Cancers Symposium 2026

    Whole genome–based ultrasensitive circulating tumor DNA clearance as a biomarker of exceptional outcomes with enfortumab vedotin and pembrolizumab in urothelial carcinoma: Preliminary real-world results.

    Zerey, Mehmet Murat · Abstract 866 · 27 patients, 118 plasma samples; single-institution retrospective

    Next Personal Dx tumor-informed whole-genome sequencing assay (up to 1,800 patient-specific variants; detection down to about 1 part per million), as stated in the abstract

    Among evaluable patients, 11 (48%) achieved ctDNA clearance after a median of 3 EVP cycles and 12 (52%) had persistent positivity. The abstract states clearance correlated with exceptional clinical and radiographic outcomes, and persistent positivity identified residual or progressive disease. Median follow-up 13.8 months; 19 of 27 remained under surveillance, including 9 with metastatic disease.

    Abstract

  • Level 2positiveASCO Genitourinary Cancers Symposium 2026

    Urinary tumor DNA (utDNA) and circulating tumor DNA (ctDNA) in patients (pts) with muscle-invasive bladder cancer (MIBC) who received perioperative durvalumab (D) in NIAGARA.

    Van Der Heijden, Michiel S. · Abstract 636 · NIAGARA · 265 biomarker-evaluable (25% of 1063 randomized)

    Signatera for ctDNA (named in the related NIAGARA ASCO 2025 abstract). utDNA as described in this abstract.

    utDNA-positive rate fell from 85% at baseline to 55% pre-cystectomy. Clearance was associated with longer EFS (HR 0.24, 95% CI 0.09-0.62) and was 12 percentage points higher with durvalumab (39% vs 27%). Pre-cystectomy utDNA-negative status was associated with pCR (72% [55/76] vs 18% [17/96] if utDNA-positive). Estimated 24-month EFS was 90% if dual-negative, 75% if utDNA-positive only, and 55% if dual-positive.

    Abstract

  • Level 1positiveASCO Genitourinary Cancers Symposium 2026

    Circulating tumor (ct)DNA-guided adjuvant atezolizumab (atezo) in muscle-invasive bladder cancer (MIBC): Exploratory analysis of ctDNA dynamics in the IMvigor011 trial.

    Powles, Thomas · Abstract 633 · IMvigor011 · 379 patients who tested ctDNA-positive during surveillance; on-treatment dynamics in 165 atezolizumab and 83 placebo

    not named in the abstract (results reported as mean tumor molecules/mL)

    Of patients first testing ctDNA-positive, 74.1% (281/379) did so within 24 weeks of radical cystectomy; early positivity and higher baseline concentration (median 0.27 MTM/mL) were associated with shorter investigator-assessed DFS. Atezolizumab decreased ctDNA levels between cycle 1 and 3 (log2 fold-change -0.4) while levels increased on placebo (log2 fold-change 0.5; Wilcoxon P=0.009). Clearance at cycle 3 or 5 was associated with improved DFS and OS.

    AbstractFull paper

  • Level 2positiveASCO Annual Meeting 2025

    Circulating tumor DNA (ctDNA) in patients with muscle-invasive bladder cancer (MIBC) who received perioperative durvalumab (D) in NIAGARA.

    Powles, Thomas · Abstract 4503 · NIAGARA · 462 biomarker-evaluable of 1063 randomized (237 durvalumab arm, 225 control)

    Signatera (named in the abstract)

    ctDNA-positive rate was 57% (260/460) at baseline and fell to 22% (94/422) after neoadjuvant treatment, pre-cystectomy. Clearance from baseline to pre-cystectomy was 41% with durvalumab plus NAC vs 31% with NAC alone. Pre-cystectomy ctDNA-positive status was associated with non-pCR in 97% (86/89). Event-free survival benefit of perioperative durvalumab was observed in both baseline ctDNA-positive and ctDNA-negative groups. Post-cystectomy ctDNA-positive rate was 9% (31/345).

    Abstract

  • Level 3prognosticASCO Annual Meeting 2025

    Association of tumor-informed ctDNA-based molecular residual disease (MRD) with clinical outcomes for upper tract urothelial cancer (UTUC).

    Ayanambakkam, Adanma · Abstract 4565 · 45 patients with stage I-IV UTUC, 349 plasma samples

    Signatera (tumor-informed)

    ctDNA detection was 70.8% in the MRD window (n=24) and 68.8% during surveillance (n=32). Positivity was associated with inferior RFS (MRD window HR 13.4, P=0.012; surveillance HR 14.46, P=0.01). 12-month RFS was 32.1% and 45.5% if positive vs 100% if negative in those windows. On multivariate analysis during surveillance, ctDNA positivity was the only factor significantly associated with poor RFS (HR 17.6, P=0.011).

    Abstract

  • Level 2positiveESMO Congress 2025

    3068O Adjuvant nivolumab vs placebo for high-risk muscle-invasive urothelial carcinoma: 5-year efficacy and ctDNA results from CheckMate 274

    Galsky, M.D. · Abstract 3068O · oral · CheckMate 274 · 709 randomized (353 nivolumab, 356 placebo); ctDNA evaluable at cycle 1 day 1 in 133 (18.8%), of whom 54 (40.6%) were ctDNA-positive

    Natera Signatera (exploratory)

    With median follow-up 43.4 months, adjuvant nivolumab improved DFS versus placebo in the ITT population (median 21.9 vs 11.0 months; HR 0.74, 95% CI 0.61-0.90). In the exploratory Signatera analysis, DFS HR was 0.35 (95% CI 0.2-0.7) in patients who were ctDNA-positive at cycle 1 day 1 (median 7.4 vs 2.8 months) and 0.99 (95% CI 0.5-1.9) in those who were ctDNA-negative.

    AbstractFull paperSlidesWebcastSlides + webcast. An ASCO or ESMO member login may be required.

  • Level 1positiveESMO Congress 2025

    LBA8 IMvigor011: A phase III trial of circulating tumour (ct)DNA-guided adjuvant atezolizumab vs placebo in muscle-invasive bladder cancer

    Powles, T.B. · Abstract LBA8 · LBA · IMvigor011 · 761 enrolled in surveillance; 250 ctDNA-positive patients randomized (167 atezolizumab, 83 placebo); 357 persistently ctDNA-negative

    not named in the abstract

    Among 250 eligible ctDNA-positive patients after cystectomy, adjuvant atezolizumab improved investigator-assessed DFS versus placebo (median 9.9 vs 4.8 months; HR 0.64, 95% CI 0.47-0.87; P=0.0047) and OS (median 32.8 vs 21.1 months; HR 0.59, 95% CI 0.39-0.90; P=0.0131). In 357 patients who remained ctDNA-negative, DFS was 95.4% at the end of 1-year monitoring and 88.4% at 2 years.

    AbstractFull paperSlidesWebcastSlides + webcast. An ASCO or ESMO member login may be required.

  • Level 3prognosticASCO Annual Meeting 2023

    Association of tumor-informed minimal residual disease (MRD) with clinical outcomes for muscle invasive bladder cancer (MIBC): A multicenter retrospective real-world analysis.

    Kommalapati, Ajitha · Abstract 3050 · 109 patients, 545 plasma samples; multicenter retrospective

    Signatera (tumor-informed)

    ctDNA positivity at the first post-surgical timepoint was associated with shorter DFS (HR 9.9, 95% CI 4.1-24; 65.79% of positive patients had recurred vs 8.45% of negative). Anytime post-cystectomy positivity: HR 25 (95% CI 5.9-103); 96.83% of persistently negative patients had no recurrence. Median lead time to imaging recurrence was 61 days. In multivariate analysis, anytime ctDNA positivity was the only significant factor associated with shorter DFS (HR 23.07).

    Abstract

Accruing studies for Bladder / urothelial

Trials

Urine tumor DNA

Liu et al., Nature Medicine 2026 (PMID 42827132), is featured with the other bladder studies below. Plasma-only analyses are labeled plasma, not utDNA. Source-type labels stay on each item.

  1. Peer-reviewed

    Verified

    utDNA

    Postresection Urinary Tumor DNA Refines Residual Disease Assessment and Recurrence Risk Stratification in Non-Muscle-Invasive Bladder Cancer

    Source

    Huang S, et al.

    JCO Precision Oncology. November 4, 2026. PMID 42981539. doi 10.1200/PO-26-00676.

    Guideline-anchored cohort analysis

    Assay: Tissue-naive urinary tumor DNA

    • In 161 patients with NMIBC who underwent repeat TURBT, tissue-naive urinary tumor DNA was collected 2 to 6 weeks after the first resection and before the second. Residual tumor was found in 57 patients (35.4%). Adding utDNA raised the AUC for residual tumor from about 0.54 to about 0.89 across guideline-based indication sets, and improved recurrence-risk discrimination beyond EAU and EORTC models (and, in the same direction, CUETO).
  2. Peer-reviewed

    plasma tumor-informed ctDNA (NOT utDNA)

    ctDNA-guided immunotherapy following radical cystectomy for muscle-invasive bladder cancer: results from the TOMBOLA trial.

    Source

    Dyrskjot L, Birkenkamp-Demtroder K, Nordentoft I, et al., including Jensen JB.

    Ann Oncol 2026;37(5):712-724.

    n: 192 enrolled, 178 assessable, median FU 34 months

    Danish multicenter, open-label, single-arm phase 2. MIBC after NAC and RC. ctDNA+ started atezolizumab up to 1 year; ctDNA- received IO only if imaging showed metastases.

    Assay: Serial tumor-informed plasma ctDNA (not utDNA)

    • 104 (58%) ctDNA+ within 2 years after RC, 63% of those within 4 months.
    • Median lead time ctDNA to imaging-confirmed recurrence: 90 days (range -61 to 961).
    • 60% (50/84) of ctDNA+ patients who completed atezo with scans/ctDNA for the primary end point achieved complete molecular and radiographic response.
    • 1-year RFS 97% if ctDNA- vs 76% if ctDNA+.
  3. Peer-reviewed

    clinical outcomes in FGFR3/2-altered NMIBC; utDNA/urine FGFR monitoring not in final abstract

    Erdafitinib in Patients with High- and Intermediate-risk Non-muscle-invasive Bladder Cancer: Final Analysis of THOR-2 Study.

    Source

    Daneshmand S, Zaucha R, Catto JWF, Tran B, Master V, Lotan Y, et al., including Maranchie JK.

    Eur Urol 2026;89(2):165-173.

    • Cohort 1 (HR papillary, prior BCG), n=73, 2:1 erdafitinib vs intravesical chemo: median RFS NR (28.6 mo-NE) vs 11.6 mo, HR 0.28 (0.13-0.61), nominal P=0.0007.
    • Cohort 2 (CIS +/- papillary), n=16: CR 94% at 8 weeks, 81% at 32 weeks; mDoR 23.3 months.
    • Cohort 3 (IR), n=18: CR 89%.

    A urine FGFR or utDNA monitoring analysis is not described in the final-paper abstract. How FGFR3/2 alterations were ascertained (tissue vs urine) is not stated in that abstract.

  4. Peer-reviewed

    Field-effect-informed urine liquid biopsy for bladder cancer.

    Source

    Shi WY, Liu KJ, Esfahani MS, Mach KE et al. Cell 2026;189(4):1024-1038.e9.

    n: 261 serial specimens from 61 NMIBC patients (validation); plus training and control analyses described in field_cancerization

    Intermediate- or high-risk NMIBC, TURBT and adjuvant BCG

    Assay: Field-effect-informed (RePhyNERX-enhanced) uCAPP-Seq, tumor-informed

  5. Peer-reviewed

    utDNA and plasma ctDNA MRD (exploratory) plus clinical end points

    Gemcitabine Intravesical System Plus Cetrelimab or Cetrelimab Alone as Neoadjuvant Therapy in Muscle-Invasive Bladder Cancer: SunRISe-4 Primary Analysis and Biomarker Results.

    Source

    Necchi A, Guerrero-Ramos F, Crispen PL, Herrera-Imbroda B, Garje R, Szabados B, Peyton CC, Pradere B, Ku JH, Shore N, Bogemann M, Preston MA, Xylinas E, Sanchez de Llano C, Gong C, Hasan M, Urtishak K, Battaglia S, Stitou H, Bhanvadia S, Sweiti H, Psutka SP (22 authors on PubMed; Galsky MD is not on this list).

    J Clin Oncol 2026;44(7):586-597. Published 3 December 2025.

    n: 159 treated; 88 cohort 1 and 46 cohort 2 underwent RC; utDNA available 67 at baseline, 65 at week 12

    Phase 2, cisplatin-ineligible or -refusing cT2-T4a N0M0 MIBC planned for RC; 5:3 randomization, cohort 1 TAR-200 + cetrelimab, cohort 2 cetrelimab alone. Data cutoff 9 May 2025.

    Assay: utDNA and ctDNA MRD; vendor and gene content not named in the abstract (vendor and gene content are not named in the abstract).

    • pCR, pOR (<=ypT1N0), 1-year RFS: 38%, 53%, 77% in cohort 1 vs 28%, 44%, 64% in cohort 2.
    • Baseline utDNA+ 55/67 (82.1%); week 12 utDNA+ 34/65 (52.3%).
    • Week-12 utDNA- and clearance correlated with pCR (P<10^-5 and P<10^-3 in abstract; Fisher P=5.4e-6 for week-12 status in results text).
    • 22/27 (81.5%) who achieved pCR were utDNA- at week 12 vs 7/33 (21.2%) who did not. ROC 0.80 (0.70-0.90); NPV 0.81.
    • Clearance in 14/30 (46.7%) with available data (7/18 C1, 7/12 C2). 12/15 (80.0%) baseline+ with pCR had clearance vs 2/15 (13.3%) without pCR.
    • ctDNA- at baseline and week 12 associated with longer RFS (P=0.04 and 0.01).
    • Authors: utDNA and ctDNA support further investigation as biomarkers for residual local and nonlocal disease, respectively.

    Not on the PubMed author list of this JCO paper. Galsky's own utDNA work is the HCRN GU16-257 PNAS 2026 paper.

  6. Peer-reviewed

    plasma ctDNA and utDNA

    Monitoring of plasma and urine tumor-derived DNA to inform bladder-sparing approaches for patients with muscle-invasive bladder cancer.

    Source

    Galsky MD, Izadmehr S, Yu M, Curtis SD, Douville C, et al., including Bettegowda, Kinzler, Papadopoulos, Vogelstein, Wang Y.

    Proc Natl Acad Sci USA 2026;123(8):e2533449123.

    Exploratory liquid biopsy in the gem/cis/nivo bladder-sparing trial; tumor-informed academic assay; authors note relatively small sample.

    Assay: Tumor-informed academic ctDNA and utDNA assay

    • 3-year bladder-intact survival among cCR after four rounds of systemic therapy: 69%.
    • Metastatic risk if pretreatment ctDNA detectable vs undetectable: HR 4.68 (1.10-43.35), P=0.036.
    • Only 4.5% (1 of 22) with undetectable baseline ctDNA developed metastatic disease.
    • utDNA more sensitive than plasma ctDNA for residual disease in the bladder.
    • Detectable utDNA in patients with cCR associated with shorter bladder-intact survival, HR 6.47 (1.34-31.31), P=0.008.

    first author — this is the Galsky utDNA study

  7. Peer-reviewed

    utDNA

    Postinduction Urine Tumor DNA Is Predictive for Response to Maintenance Intravesical Therapy in NMIBC.

    Source

    Lotan Y, Korman H, Gadzinski A, et al.

    Eur Urol Oncol 2026. INSITE, observational.

    n: 140 evaluable, 47% received maintenance

    • utDNA-: no significant RFS benefit from maintenance (HR 1.35, 0.50-3.64, P=0.6); 24-month RFS 88% with or without maintenance.
    • utDNA+: maintenance associated with better RFS (HR 0.22, 0.09-0.52, P<0.001); 24-month RFS 68% with maintenance vs 16% without.
    • Observational; not a randomized test of utDNA-guided maintenance.
  8. Conference abstract

    utDNA and plasma ctDNA

    Urinary tumor DNA (utDNA) and circulating tumor DNA (ctDNA) in patients with MIBC who received perioperative durvalumab in NIAGARA.

    Source

    J Clin Oncol 2026;44(7_suppl):636. ASCO GU 2026. Conference abstract; not a full paper.

    n: BEP 265 of 1063 (25%; 134 D, 131 C); utDNA at BL n=205, pre-RC n=183

    Exploratory utDNA + ctDNA in NIAGARA, cisplatin-eligible MIBC, pre-cystectomy

    Assay: Personalized Signatera (Natera), same framework as the plasma test

    • Lower baseline utDNA associated with longer EFS (low vs high HR 0.65, 95% CI 0.40-1.04).
    • utDNA+ rate 85% at baseline, 55% pre-RC.
    • utDNA clearance associated with longer EFS (HR 0.24, 95% CI 0.09-0.62); clearance 39% vs 27% (12 points higher with durvalumab).
    • Pre-RC utDNA-: pCR 72% (55/76) vs 18% (17/96) if utDNA+.
    • utDNA+ correlated with noninvasive residual disease (<T2N0M0); ctDNA+ with invasive disease or N+/M+.
    • 24-month EFS: dual-negative 90% (83-97), utDNA+ only 75% (65-87), dual-positive 55% (41-75).

    Conference abstract, exploratory, 25% of ITT. Full paper not found in PubMed.

    UroToday interview, Michiel van der Heijden. Interview commentary (e.g. plasma thresholds used for urine) is not a paper result.

  9. Peer-reviewed

    Urine cell-free RNA for bladder cancer detection and treatment response prediction.

    Source

    Liu KJ, Shi WY, Nesselbush MC, Phillips NA, Mach KE, et al.; Alizadeh AA, Liao JC, and Diehn M senior.

    Nat Med. Published 2 October 2026. Open access on the Nature page.

    n: 683 urine samples from patients with cancer and controls

    Detection, MRD, and BCG-versus-chemotherapy response prediction in bladder cancer; also transcripts from prostate and kidney cancers noted.

    Assay: uRARE-seq (urine random priming and affinity capture of cell-free RNA fragments for enrichment analysis by sequencing)

    • 95% sensitivity at 90% specificity for detecting localized bladder cancer.
    • Outperformed urine tumor DNA analysis and was unaffected by field-effect mutations.
    • Sensitively detected MRD and distinguished complete molecular responses after surgery from those after BCG.
    • Pretreatment urine from BCG complete responders enriched for T-cell and other immune signatures; nonresponders showed higher proliferation-related gene expression.
    • In pretreatment urine from 114 patients, a biomarker predicting BCG versus chemotherapy response had AUC 0.93 and was strongly associated with recurrence risk.
    • Authors state prospective studies are needed to assess clinical utility.
  10. Bibliographic catalog

    Additional verified 2025-2026 utDNA citations

  11. Conference abstract

    plasma ctDNA (not utDNA)

    Circulating tumor DNA (ctDNA) in patients with MIBC who received perioperative durvalumab in NIAGARA.

    Source

    J Clin Oncol 2025;43(16_suppl):4503.

    n: BEP 462 of 1063 (237 D, 225 C)

    Exploratory plasma ctDNA in NIAGARA

    Assay: Signatera, tumor-informed (Natera)

    • Baseline ctDNA+ 57% (260/460), pre-RC 22% (94/422).
    • Clearance baseline to pre-RC: 41% durvalumab vs 31% comparator.
    • Non-pCR 97% (86/89) if pre-RC ctDNA+.
    • Post-RC ctDNA+ 9% (31/345).
    • EFS benefit of durvalumab reported in both baseline ctDNA+ and ctDNA- groups.
  12. Peer-reviewed

    clinical (utDNA not in main abstract)

    TAR-200 for BCG-Unresponsive High-Risk NMIBC: Results From the Phase IIb SunRISe-1 Study.

    Source

    Daneshmand S, Van der Heijden MS, Jacob JM, et al., including Necchi A.

    J Clin Oncol 2025;43(33):3578-3588.

    • The main paper’s abstract does not report utDNA. Complete numeric utDNA results from ESMO 2025 abstract 3088P were not extracted from the primary abstract, so those rates are not shown.

    ESMO 2025 abstract 3088P (Ann Oncol, S0923-7534(25)04622-8) and a J&J Medical Connect congress PDF address molecular markers including baseline urinary tumor DNA MRD. Complete numeric utDNA results were not independently extracted from the primary abstract. Rates from that abstract are not included.

  13. Conference abstract

    Urine cell-free RNA analysis for bladder cancer detection and monitoring.

    Source

    Liu, Shi, Nesselbush, Phillips et al., including Alizadeh, Liao, Diehn. Cancer Res 2025;85(8_Suppl_1):Abstract 3773. AACR 2025.

    n: 414 urine samples from 213 non-malignant controls and 201 BLCA patients (160 NMIBC, 41 MIBC)

    • Locked model: 95% sensitivity at 90% specificity; independent validation 94% sensitivity and 88% specificity; LOD 0.05%.
    • Sensitivity: 86% low-grade Ta, 97% high-grade Ta, 100% high-grade CIS, 100% high-grade tumors greater than T1.
    • 37 post-BCG samples: residual BLCA cfRNA associated with recurrence, HR 42.27, log-rank P < 0.0001.
    • Grade model AUC 0.85; NMIBC vs MIBC AUC 0.82.
  14. Peer-reviewed

    utDNA (UroAmp)

    Urine Tumor DNA to Stratify the Risk of Recurrence in Patients Treated with Atezolizumab for BCG-unresponsive NMIBC.

    Source

    St-Laurent MP, Singh P, McConkey DJ, et al., including Lerner SP, Black PC.

    Eur Urol 2025;88(5):430-434. SWOG S1605.

    n: UroAmp at baseline n=89 and 3 months n=77

    Assay: UroAmp

    • CR at 6 months: 13% of UroAmp+ vs 71% of UroAmp- at baseline (P<0.001).
    • 18-month EFS 23% vs 51% (HR 2.8, P<0.001).
    • Among 51 with no clinical evidence of disease at 3 months: 18-month EFS 38% if UroAmp+ vs 86% if negative (HR 3.5, P=0.01).
  15. Peer-reviewed

    multitarget urine tumor DNA (mutations + methylation)

    Clinical effectiveness of a multitarget urine DNA test for urothelial carcinoma detection: a double-blinded, multicenter, prospective trial.

    Source

    Wu J, Lin Y, Yang K, et al.

    Mol Cancer 2024;23(1):57. UI-Seek.

    n: Development 382; prospective validation 947 (ChiCTR2300076543)

    Assay: FGFR3 and TERT mutations plus ONECUT2 and VIM methylation

    • Sensitivity 91.37%, specificity 95.09%.
    • 75.81% for low-grade Ta; >93% for high-grade Ta and higher stages; >90% for both bladder and upper-tract tumors.
    • Post-surgery UC-score decreased in 97.7% (43/44).
  16. Peer-reviewed

    utDNA methylation (BladMetrix)

    Distinct longitudinal patterns of urine tumor DNA in patients undergoing surveillance for bladder cancer.

    Source

    Vedeld HM, et al.

    Mol Oncol 2024;18(11):2684-2695.

    n: 47 patients, 2-year surveillance

    • Detected 21/23 recurrences (91%): 5/5 T1, T2, and CIS (100%) and 10/12 Ta (83%); <1% false-negative tests.
    • Authors estimate a potential 55% reduction in cystoscopies, benefiting 79% of patients (estimate from the paper, not a randomized result).
    • 11/23 recurrences (48%) detected earlier with utDNA than cystoscopy.
    • Residual-utDNA patterns interpreted as MRD in 6% and field effect in 15%.
  17. Peer-reviewed

    clinical trial (not utDNA; context)

    Perioperative Durvalumab with Neoadjuvant Chemotherapy in Operable Bladder Cancer.

    Source

    Powles T, Catto JWF, Galsky MD, et al., including van der Heijden MS, NIAGARA Investigators.

    N Engl J Med 2024;391(19):1773-1786.

    n: 1063 (533 durvalumab, 530 comparison)

    Phase 3, cisplatin-eligible MIBC

    Assay: n/a (clinical end points)

    • 24-month EFS 67.8% vs 59.8%, HR 0.68 (0.56-0.82), P<0.001.
    • 24-month OS 82.2% vs 75.2%, HR 0.75 (0.59-0.93), P=0.01.

    co-author

  18. Peer-reviewed

    clinical bladder-sparing (context for utDNA follow-up)

    Gemcitabine and cisplatin plus nivolumab as organ-sparing treatment for muscle-invasive bladder cancer: a phase 2 trial.

    Source

    Galsky MD, Daneshmand S, Izadmehr S, et al.

    Nat Med 2023;29(11):2825-2834.

    n: 76

    • cCR 43% (33/76, 95% CI 32-55%); 32 of 33 with cCR opted to forgo immediate cystectomy; PPV of cCR 0.97 (0.91-1).
  19. Peer-reviewed

    utDNA multi-omics

    Urine cell-free DNA multi-omics to detect MRD and predict survival in bladder cancer patients.

    Source

    Chauhan PS, Shiang A, Alahi I, et al., including Chaudhuri AA.

    NPJ Precis Oncol 2023;7(1):6.

    n: 74

    Localized bladder cancer

    Assay: ULP-WGS plus uCAPP-Seq

    • Random-forest LOOCV 87% sensitive for residual disease vs surgical pathology.
    • PFS HR 3.00, P=0.01; OS HR 4.81, P=0.009.
    • Urine metrics predicted pCR 'far better than plasma ctDNA was able to.'
  20. Peer-reviewed

    urinary tumor-derived DNA plus multi-omics

    Elevated T-cell Exhaustion and Urinary Tumor DNA Levels Are Associated with BCG Failure in Patients with NMIBC.

    Source

    Strandgaard T, Lindskrog SV, Nordentoft I, Christensen E, Birkenkamp-Demtroder K, et al., including Jensen JB, Dyrskjot L.

    Eur Urol 2022;82(6):646-656.

    n: 156 BCG-treated NMIBC; urine tdDNA n=187 samples

    • Absence of post-BCG tdDNA clearance identified patients at high risk of recurrence (P=0.018).
    • Post-BCG HG recurrence associated with T-cell exhaustion (P=0.002).
  21. Peer-reviewed

    utDNA

    Urine tumor DNA detection of minimal residual disease in muscle-invasive bladder cancer treated with curative-intent radical cystectomy: A cohort study.

    Source

    Chauhan PS, Chen K, Babbra RK, et al., including Smith ZL, Arora VK, Chaudhuri AA.

    PLoS Med 2021;18(8):e1003732.

    n: 42 localized bladder cancer (32 MIBC, 19 of those with NAC) and 15 healthy adults

    Urine on the day of curative-intent RC

    Assay: uCAPP-Seq, tumor-naive (Diehn-group method; WashU / Chaudhuri lab, not a Diehn-lab paper)

    • Median utDNA 0% healthy vs 2.4% patients; 4.3% if residual disease (n=16) vs 0% if pCR (n=26), P=0.002.
    • utDNA MRD vs absence of pCR: sensitivity 81%, specificity 81%; LOO accuracy 81% (P=0.007).
    • PFS HR 7.4 (1.4-38.9), P=0.02.
    • Mutation concordance with tumor in 5 patients: 85%.
  22. Peer-reviewed

    tissue/immune biomarkers; utDNA not in abstract

    Clinical efficacy and biomarker analysis of neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trial.

    Source

    Powles T, Kockx M, Rodriguez-Vida A, et al.

    Nat Med 2019.

    n: 95

    • pCR 31% (95% CI 21-41%). Biomarkers are tissue and immune contexture; utDNA is not reported in the abstract.
  23. Peer-reviewed

    Detection and Surveillance of Bladder Cancer Using Urine Tumor DNA.

    Source

    Dudley JC, Schroers-Martin J, Lazzareschi DV, Shi WY, Chen SB, Esfahani MS, Trivedi D, Chabon JJ, Chaudhuri AA, et al.; Alizadeh AA and Diehn M senior.

    Cancer Discov 2019.

    n: 67 healthy adults and 118 patients with early-stage bladder cancer

    Pretreatment or surveillance, early-stage BLCA

    Assay: uCAPP-Seq (utDNA CAPP-Seq), targeted high-throughput sequencing

    • Median 6 mutations per patient; PLEKHS1 promoter mutations in 46%.
    • Pretreatment detection 93% tumor-informed, 84% tumor-naive, 96% to 100% specificity.
    • Surveillance: utDNA detected in 91% of patients who ultimately recurred; preceded clinical progression in 92% (median lead time 2.7 months in the full text).
    • Outperformed UroVysion (P=0.02) and cytology and cystoscopy combined (P<=0.006); detected 100% of cytology-positive cases and 82% that cytology missed (abstract).
    • Surveillance subset in full text: tumor-naive profiling detected 100% of recurrent cases with positive cytology (n=14) and 73.9% with negative cytology (n=23).
  24. Peer-reviewed

    plasma ctDNA (NOT utDNA)

    Early Detection of Metastatic Relapse and Monitoring of Therapeutic Efficacy by Ultra-Deep Sequencing of Plasma Cell-Free DNA in Patients With Urothelial Bladder Carcinoma.

    Source

    Christensen E, Birkenkamp-Demtroder K, Sethi H, et al., including Dyrskjot L.

    J Clin Oncol 2019;37(18):1547-1557.

    n: 68 patients, 656 plasma samples

    Assay: Tumor-informed ultra-deep sequencing (median 105,000x)

    • ctDNA at diagnosis HR 29.1, P=0.001.
    • After cystectomy, ctDNA identified metastatic relapse with 100% sensitivity and 98% specificity; median lead time 96 days.
    • ctDNA dynamics during chemo associated with recurrence (P=0.023); pathologic downstaging was not.
  25. Peer-reviewed

    urine DNA (mutations + aneuploidy)

    Non-invasive detection of urothelial cancer through the analysis of driver gene mutations and aneuploidy.

    Source

    Springer SU, Chen CH, Rodriguez Pena MDC, et al., including Papadopoulos, Kinzler, Vogelstein, Netto.

    eLife 2018;7:e32143.

    n: 570 at risk for BC; 56 UTUC; surveillance subset

    Assay: UroSEEK: 11 genes plus copy-number changes on 39 chromosome arms

    • Positive in 83% of those who developed BC; combined with cytology, 95%.
    • UTUC: 75% of 56 positive (79% of non-invasive tumors).
    • Surveillance: genetic abnormalities in 68% of urines from patients with clinical recurrence.
    • Low-grade BC: UroSEEK 67%, cytology 0%.

FDA approves adjuvant atezolizumab for ctDNA MRD-positive MIBC, with Signatera CDx

On May 15, 2026, the FDA approved atezolizumab and atezolizumab/hyaluronidase as adjuvant treatment for adults with muscle-invasive bladder cancer after cystectomy who have ctDNA molecular residual disease on an FDA-authorized test, and approved Signatera CDx to select those patients; in IMvigor011 median disease-free survival was 9.9 versus 4.8 months (HR 0.64) and median overall survival was 32.8 versus 21.1 months (HR 0.59).

U.S. FDA

IMvigor011: ctDNA-guided adjuvant atezolizumab improved DFS and OS in MIBC

In the phase 3 IMvigor011 trial published in NEJM, 250 of 761 monitored patients with muscle-invasive bladder cancer tested ctDNA-positive after cystectomy and were randomized to atezolizumab or placebo, with median disease-free survival of 9.9 versus 4.8 months (HR 0.64) and median overall survival of 32.8 versus 21.1 months (HR 0.59); persistently ctDNA-negative patients were not treated on study and had a 95% disease-free survival at 1 year.

New England Journal of Medicine

Real-world adoption of circulating tumor DNA testing and adjuvant treatment decisions after radical cystectomy for muscle-invasive bladder cancer

In a Flatiron Health analysis of 4,533 people after radical cystectomy for muscle-invasive bladder cancer, documented Signatera testing 4-24 weeks after surgery increased over time (OR 1.16 per quarter) and was more common in high-risk pathology, but among 200 patients whose result preceded the treatment decision, detectable ctDNA was not independently associated with adjuvant therapy after adjustment (adjusted RR 1.34, 95% CI 0.89-2.02), while high-risk pathology was (adjusted RR 9.45).

ESMO Open

Circulating Tumor DNA Clearance Is Associated with Response and Survival in Metastatic Urothelial Carcinoma Treated with First-Line Enfortumab Vedotin Plus Pembrolizumab

In this single-center retrospective study of 25 patients with metastatic urothelial carcinoma treated with first-line enfortumab vedotin plus pembrolizumab, a tumor-informed assay (Signatera) measured ctDNA over time. Fifteen of 25 patients (60%) achieved ctDNA clearance (ever undetectable); the objective response rate was 76% overall and 100% (15/15) with clearance versus 40% (4/10) without (p = 0.0012). Clearance was associated with longer PFS (HR 0.16, 95% CI 0.05–0.54; p = 0.003) and OS (HR 0.08, 95% CI 0.01–0.68; p = 0.021), although these associations were attenuated in a time-dependent analysis (PFS HR 0.35, 95% CI 0.09–1.15, p = 0.085; OS HR 0.14, 95% CI 0.01–0.84, p = 0.029).

CancersPMID 43026853DOI

Perioperative durvalumab ± tremelimumab plus neoadjuvant enfortumab vedotin in cisplatin-ineligible MIBC: phase 3 VOLGA (NCT04960709)

Exploratory Signatera Genome ctDNA results from the durvalumab plus enfortumab vedotin arm of phase 3 VOLGA (NCT04960709), presented by Thomas Powles at ESMO Congress 2026 (Presidential Symposium I, LBA2, October 24, 2026), covered 112 patients with matched evaluable samples at baseline and before cystectomy as of July 2026: 87 of 112 (78%) were ctDNA-positive at baseline, 52 of those 87 (60%) cleared ctDNA before cystectomy, 76 of 112 (68%) were ctDNA-negative before cystectomy, and 24-month event-free survival was 91% if persistently negative, 81% after clearance, and 55% if persistently positive; the New England Journal of Medicine report of the trial does not include these ctDNA results.

New England Journal of MedicineUroTodayUrology TimesESMO slides, ESMO login requiredESMO webcast, ESMO login requiredOncologyPRO abstractDOI